Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?

Spierings J, van den Ende CHM, Schriemer RM, Moens HJB, van der Bijl EA, Bonte-Mineur F, de Buck MPD, de Kanter MAE, Knaapen-Hans HKA, van Laar JM, Mulder UDJ, Potjewijd J, de Pundert LAJ, Schoonbrood THM, Schouffoer AA, Stel AJ, Vercoutere W, Voskuyl AE, de Vries-Bouwstra JK, Vonk MC.

Rheumatology (Oxford). 2019 Sep 20. pii: kez417. doi: 10.1093/rheumatology/kez417. [Epub ahead of print]

PMID:
31539063
2.

Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review.

Ciaffi J, van Leeuwen NM, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK.

Semin Arthritis Rheum. 2019 Jul 20. pii: S0049-0172(19)30298-7. doi: 10.1016/j.semarthrit.2019.07.007. [Epub ahead of print] Review.

PMID:
31362894
3.

Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients With Systemic Sclerosis.

van Wijngaarden SE, Boonstra M, Bloem B, Cassani D, Tanner FC, Jordan S, Distler O, Delgado V, Bax JJ, de Vries-Bouwstra JK, Ajmone Marsan N.

JACC Cardiovasc Imaging. 2019 Jul 11. pii: S1936-878X(19)30536-4. doi: 10.1016/j.jcmg.2019.05.017. [Epub ahead of print] No abstract available.

PMID:
31326475
4.

Degree of Vasculopathy in Systemic Sclerosis Patients with Anti-U3RNP Antibody Indicates Need for Extensive Cardiopulmonary Screening.

VAN Leeuwen NM, Boonstra M, Ajmone Marsan N, Ninaber MK, Huizinga TWJ, DE Vries-Bouwstra JK.

J Rheumatol. 2019 Sep;46(9):1244-1245. doi: 10.3899/jrheum.181378. Epub 2019 Jul 1. No abstract available.

PMID:
31263069
5.

OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis.

Takata M, Pachera E, Frank-Bertoncelj M, Kozlova A, Jüngel A, Whitfield ML, Assassi S, Calcagni M, de Vries-Bouwstra J, Huizinga TW, Kurreeman F, Kania G, Distler O.

Front Immunol. 2019 May 17;10:1100. doi: 10.3389/fimmu.2019.01100. eCollection 2019.

6.

Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis.

de Vries-Bouwstra J, Allanore Y, Matucci-Cerinic M, Balbir-Gurman A.

J Rheumatol. 2019 May 1. pii: jrheum.181173. doi: 10.3899/jrheum.181173. [Epub ahead of print]

PMID:
31043545
7.

Living with systemic sclerosis: exploring its impact on caregivers.

Schriemer MR, Spierings J, De Vries-Bouwstra JK, de Pundert LAJ, van den Ende CH, Vonk MC.

Disabil Rehabil. 2019 Apr 30:1-2. doi: 10.1080/09638288.2019.1608320. [Epub ahead of print] No abstract available.

PMID:
31038365
8.

Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Chadli L, Sotthewes B, Li K, Andersen SN, Cahir-McFarland E, Cheung M, Cullen P, Dorjée A, de Vries-Bouwstra JK, Huizinga TWJ, Fischer DF, DeGroot J, Viney JL, Zheng TS, Aarbiou J, Gardet A.

Sci Rep. 2019 Mar 14;9(1):4521. doi: 10.1038/s41598-019-41153-w.

9.

Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study.

van Wijngaarden SE, Ben Said-Bouyeri S, Ninaber MK, Huizinga TWJ, Schalij MJ, Bax JJ, Delgado V, de Vries-Bouwstra JK, Marsan NA.

J Rheumatol. 2019 Apr;46(4):405-415. doi: 10.3899/jrheum.171207. Epub 2019 Mar 1.

PMID:
30824646
10.

Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.

Boonstra M, Ninaber MK, Ajmone Marsan N, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

Rheumatology (Oxford). 2019 Apr 1;58(4):730-732. doi: 10.1093/rheumatology/kez005. No abstract available.

PMID:
30690619
11.

Optimal care for systemic sclerosis patients: recommendations from a patient-centered and multidisciplinary mixed-method study and working conference.

Spierings J, van den Ende C, Schriemer R, de Pundert L, Moens HB, van Laar J, de Vries-Bouwstra J, Vonk M.

Clin Rheumatol. 2019 Apr;38(4):1007-1015. doi: 10.1007/s10067-018-4358-x. Epub 2018 Nov 17.

PMID:
30448933
12.

Systemic sclerosis: state of the art on clinical practice guidelines.

Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M.

RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018.

13.

Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort.

Morrisroe K, Hudson M, Baron M, de Vries-Bouwstra J, Carreira PE, Wuttge DM, Wang M, Frech TM, Stevens W, Proudman SM, Nikpour M; International Systemic Sclerosis Inception Cohort (INSYNC) collaboration.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):53-60. Epub 2018 Aug 31.

14.

To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?

Boonstra M, Mertens BJA, Bakker JA, Ninaber MK, Ajmone Marsan N, van der Helm-van Mil AHM, Scherer HU, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):109-117. Epub 2018 Jul 18.

PMID:
30148428
15.

A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.

van Rhijn-Brouwer FCC, Gremmels H, Fledderus JO, Schuurman AH, Bonte-Mineur F, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Coert JH, Radstake TRDJ, van Laar JM, Verhaar MC; MANUS Study Group.

BMJ Open. 2018 Aug 20;8(8):e020479. doi: 10.1136/bmjopen-2017-020479.

16.

ECG derived ventricular gradient exceeds echocardiography in the early detection of pulmonary hypertension in scleroderma patients.

Meijer FMM, Kies P, Jongbloed MRM, van Wijngaarden SE, Swenne CA, Man S, Schalij MJ, de Vries-Bouwstra JK, Vliegen HW.

Int J Cardiol. 2018 Dec 15;273:203-206. doi: 10.1016/j.ijcard.2018.07.122. Epub 2018 Jul 24.

PMID:
30097334
17.

A case of late-onset systemic sclerosis with ruptured silicone breast implants.

Meijs J, de Vries-Bouwstra JK, Cohen Tervaert JW, Hoogenberg K.

Neth J Med. 2018 Jul;76(5):243-248.

18.

Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis.

Messemaker TC, Chadli L, Cai G, Goelela VS, Boonstra M, Dorjée AL, Andersen SN, Mikkers HMM, van 't Hof P, Mei H, Distler O, Draisma HHM, Johnson ME, Orzechowski NM, Simms RW, Toes REM, Aarbiou J, Huizinga TW, Whitfield ML, DeGroot J, de Vries-Bouwstra J, Kurreeman F.

J Invest Dermatol. 2018 Apr;138(4):826-835. doi: 10.1016/j.jid.2017.09.053. Epub 2017 Nov 24.

19.

Physical activity in patients with systemic sclerosis.

Liem SIE, Meessen JMTA, Wolterbeek R, Ajmone Marsan N, Ninaber MK, Vliet Vlieland TPM, de Vries-Bouwstra JK.

Rheumatol Int. 2018 Mar;38(3):443-453. doi: 10.1007/s00296-017-3879-y. Epub 2017 Nov 18.

20.

Rituximab in early systemic sclerosis.

Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

RMD Open. 2017 Jul 28;3(2):e000384. doi: 10.1136/rmdopen-2016-000384. eCollection 2017.

21.

An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.

Bossini-Castillo L, Campillo-Davó D, López-Isac E, Carmona FD, Simeon CP, Carreira P, Callejas-Rubio JL, Castellví I, Fernández-Nebro A, Rodríguez-Rodríguez L, Rubio-Rivas M, García-Hernández FJ, Madroñero AB, Beretta L, Santaniello A, Lunardi C, Airó P, Hoffmann-Vold AM, Kreuter A, Riemekasten G, Witte T, Hunzelmann N, Vonk MC, Voskuyl AE, de Vries-Bouwstra J, Shiels P, Herrick A, Worthington J, Radstake TRDJ, Martin J; Spanish Scleroderma Group.

J Rheumatol. 2017 Oct;44(10):1453-1457. doi: 10.3899/jrheum.161369. Epub 2017 Jul 1.

PMID:
28668810
22.

Auto-antibodies and cancer in systemic sclerosis.

Boonstra M, Huizinga TWJ, de Vries-Bouwstra JK.

Autoimmun Rev. 2017 Aug;16(8):883-884. doi: 10.1016/j.autrev.2017.05.023. Epub 2017 May 29. No abstract available.

23.

Lung Density and Pulmonary Artery Diameter are Predictors of Pulmonary Hypertension in Systemic Sclerosis.

Bakker ME, Ninaber MK, Stolk J, Kroft LJM, Schouffoer AA, de Vries Bouwstra JK, van Wijngaarden SE, Stoel BC.

J Thorac Imaging. 2017 Nov;32(6):391-397. doi: 10.1097/RTI.0000000000000279.

PMID:
28549020
24.

Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.

Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z, de Vries-Bouwstra J, Del Papa N, Saccardi R, Shah SJ, Lee DC, Denton C, Alexander T, Kiely DG, Snowden JA.

Bone Marrow Transplant. 2017 Nov;52(11):1495-1503. doi: 10.1038/bmt.2017.56. Epub 2017 May 22. Review.

25.

Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.

López-Isac E, Bossini-Castillo L, Palma AB, Assassi S, Mayes MD, Simeón CP, Ortego-Centeno N, Vicente E, Tolosa C, Rubio-Rivas M, Román-Ivorra JA, Beretta L, Moroncini G, Hunzelmann N, Distler JHW, Riemekasten G, de Vries-Bouwstra J, Voskuyl AE, Radstake TRDJ, Herrick A, Denton CP, Fonseca C, Martín J.

Arthritis Rheumatol. 2017 Jun;69(6):1337-1338. doi: 10.1002/art.40058. Epub 2017 May 9. No abstract available.

26.

Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies.

Markusse IM, Meijs J, de Boer B, Bakker JA, Schippers HPC, Schouffoer AA, Ajmone Marsan N, Kroft LJM, Ninaber MK, Huizinga TWJ, de Vries-Bouwstra JK.

Rheumatology (Oxford). 2017 Jul 1;56(7):1081-1088. doi: 10.1093/rheumatology/kew402.

PMID:
27940596
27.

Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies.

López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ; Spanish Scleroderma Group, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JH, Riekemasten G, van der Helm-van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg Ø, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Worthington J, Mayes MD, Martín J.

Arthritis Rheumatol. 2016 Sep;68(9):2338-44. doi: 10.1002/art.39730.

28.

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis.

Meijs J, Schouffoer AA, Ajmone Marsan N, Kroft LJ, Stijnen T, Ninaber MK, Huizinga TW, Vliet Vlieland TP, de Vries-Bouwstra JK.

RMD Open. 2016 Mar 15;2(1):e000159. doi: 10.1136/rmdopen-2015-000159. eCollection 2016.

29.

A prediction model for progressive disease in systemic sclerosis.

Meijs J, Schouffoer AA, Ajmone Marsan N, Stijnen T, Putter H, Ninaber MK, Huizinga TW, de Vries-Bouwstra JK.

RMD Open. 2015 Dec 1;1(1):e000113. doi: 10.1136/rmdopen-2015-000113. eCollection 2015.

30.

Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis.

Yiu KH, Ninaber MK, Kroft LJ, Schouffoer AA, Stolk J, Scherer HU, Meijs J, de Vries-Bouwstra J, Tse HF, Delgado V, Bax JJ, Huizinga TW, Marsan NA.

Rheumatology (Oxford). 2016 Mar;55(3):504-12. doi: 10.1093/rheumatology/kev342. Epub 2015 Oct 15.

PMID:
26472568
31.

Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.

López-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, García de la Peña P; Spanish Scleroderma Group, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Herrick A, Worthington J, Denton CP, Fonseca C, Radstake TR, Mayes MD, Martín J.

Ann Rheum Dis. 2016 Aug;75(8):1521-6. doi: 10.1136/annrheumdis-2015-208154. Epub 2015 Sep 2.

32.

Lung structure and function relation in systemic sclerosis: application of lung densitometry.

Ninaber MK, Stolk J, Smit J, Le Roy EJ, Kroft LJ, Bakker ME, de Vries Bouwstra JK, Schouffoer AA, Staring M, Stoel BC.

Eur J Radiol. 2015 May;84(5):975-9. doi: 10.1016/j.ejrad.2015.01.012. Epub 2015 Jan 22.

PMID:
25650330
33.

Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.

Markusse IM, de Vries-Bouwstra JK, Han KH, van der Lubbe PA, Schouffoer AA, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2014 Sep 25;16(5):430. doi: 10.1186/s13075-014-0430-3.

34.

Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus.

López-Isac E, Bossini-Castillo L, Guerra SG, Denton C, Fonseca C, Assassi S, Zhou X, Mayes MD, Simeón CP, Ortego-Centeno N, Castellví I, Carreira P; Spanish Scleroderma Group, Gorlova O, Beretta L, Santaniello A, Lunardi C, Hesselstrand R, Nordin A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Koeleman BP, Herrick A, Worthington J, Radstake TR, Martin J.

Arthritis Rheumatol. 2014 Dec;66(12):3521-3. doi: 10.1002/art.38870. No abstract available.

35.

Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up.

van den Broek M, Dirven L, de Vries-Bouwstra JK, Dehpoor AJ, Goekoop-Ruiterman YP, Gerards AH, Kerstens PJ, Huizinga TW, Lems W, Allaart CF.

Ann Rheum Dis. 2012 Sep;71(9):1530-3. doi: 10.1136/annrheumdis-2011-201212. Epub 2012 Apr 24.

PMID:
22532630
36.

No impact of serum uric acid on the outcome of recent-onset arthritis.

Luczak A, Knevel R, Huizinga TW, van Nies JA, van der Helm-van Mil A, De Vries-Bouwstra JK.

Ann Rheum Dis. 2012 Aug;71(8):1424-5. doi: 10.1136/annrheumdis-2011-201027. Epub 2012 Mar 22. No abstract available.

PMID:
22440824
37.

Diagnostic value of performing chest x-rays in patients presenting with recent-onset arthritis.

de Vries-Bouwstra JK, Huizinga TW, Willems LN, van der Helm-van Mil AH.

Ann Rheum Dis. 2012 Apr;71(4):627-8. doi: 10.1136/annrheumdis-2011-200319. Epub 2011 Nov 21. No abstract available.

PMID:
22110123
38.

Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.

Güler-Yüksel M, Allaart CF, Watt I, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Schaardenburg D, van Krugten MV, Dijkmans BA, Huizinga TW, Lems WF, Kloppenburg M.

Osteoarthritis Cartilage. 2010 Oct;18(10):1256-62. doi: 10.1016/j.joca.2010.07.011. Epub 2010 Aug 5.

39.

A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.

Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2010 Jul;69(7):1333-7. doi: 10.1136/ard.2009.121160. Epub 2010 May 24.

PMID:
20498212
40.

Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.

Güler-Yüksel M, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van der Kooij SM, Gerards AH, Ronday HK, Huizinga TW, Dijkmans BA, Allaart CF, Lems WF.

Arthritis Res Ther. 2010;12(3):R96. doi: 10.1186/ar3025. Epub 2010 May 20.

41.

Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.

Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, Speyer I, de Vries-Bouwstra JK, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2010 Jul;69(7):1342-5. doi: 10.1136/ard.2009.124180. Epub 2010 May 14.

PMID:
20472597
42.

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.

van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, van Zeben D, Hulsmans HM, de Jonge-Bok JM, de Sonnaville PB, Dijkmans BA, Breedveld FC.

Arthritis Rheum. 2009 Mar 15;61(3):291-9. doi: 10.1002/art.24169.

43.

DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis.

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, Speyer I, Seys PE, Breedveld FC, Allaart CF, Dijkmans BA.

Ann Rheum Dis. 2010 Jan;69(1):65-9. doi: 10.1136/ard.2008.097683.

PMID:
19155234
44.

Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.

van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, Kerstens PJ, Peeters AJ, van Zeben D, Breedveld FC, Huizinga TW, Dijkmans BA, Allaart CF.

Arthritis Rheum. 2009 Jan 15;61(1):4-12. doi: 10.1002/art.24367.

45.

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.

van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2009 Jul;68(7):1153-8. doi: 10.1136/ard.2008.093294. Epub 2008 Oct 17.

PMID:
18930988
46.

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.

van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, van der Lubbe PA, de Beus WM, Grillet BA, Ronday HK, Huizinga TW, Breedveld FC, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2009 Jun;68(6):914-21. doi: 10.1136/ard.2008.092254. Epub 2008 Jul 28.

PMID:
18662933
47.

Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.

de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF.

Arthritis Rheum. 2008 May;58(5):1293-8. doi: 10.1002/art.23439.

48.

Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.

Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallée C, de Bois MH, Breedveld FC, Dijkmans BA, Lems WF.

Ann Rheum Dis. 2009 Mar;68(3):330-6. doi: 10.1136/ard.2007.086348. Epub 2008 Mar 28.

PMID:
18375540
49.

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA.

Arthritis Rheum. 2008 Feb;58(2 Suppl):S126-35. doi: 10.1002/art.23364.

50.

Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.

Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-Bouwstra JK, Allaart CF, Drijfhout JW, de Vries RR, Breedveld FC, Huizinga TW, Pruijn GJ, Toes RE.

Arthritis Rheum. 2007 Dec;56(12):3949-52.

Supplemental Content

Loading ...
Support Center